Pair Name	Salvianolic acid B, Celecoxib
Disease Info	[ICD-11: 2C31.Z]	Head and neck squamous cell carcinoma		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	COX2	hsa4513
	Down-regulation	Expression	EGFR	hsa1956
	Up-regulation	Expression	TP53	hsa7157
In Vitro Model	JHU-06	Tongue squamous cell carcinoma	Homo sapiens (Human)	CVCL_5985
	JHU-011	Laryngeal squamous cell carcinoma	Homo sapiens (Human)	CVCL_5986
	JHU-013	Hypopharyngeal squamous cell carcinoma	Homo sapiens (Human)	CVCL_5988
	JHU-022	Laryngeal squamous cell carcinoma	Homo sapiens (Human)	CVCL_5991
In Vivo Model	JHU-013 cells (2×10⁶ cells/100 μl/mouse) were injected subcutaneously into the lower backs of the mice using a 25-gauge needle in left and right sides.
Result	These results strongly suggest that combination of Sal-B, a multifunctional anticancer agent, with low-dose celecoxib holds potential as a new preventive strategy in targeting inflammatory-associated tumor development.